Skip to content

Robert A. Soskin

United States Department of Veterans Affairs

4 papers in the library · 193 citations · publishing 1970-1976

Papers

LYSERGIC ACID DIETHYLAMIDE AS A VARIABLE IN THE HOSPITAL TREATMENT OF ALCOHOLISM

The Journal of Nervous and Mental Disease February 1, 1970 William T. Bowen, Robert A. Soskin, John W. Chotlos 68 citations

The use of LSD in treating alcoholism shows negligible long-term benefits. Patients who received LSD as part of a Human Relations Training Laboratory program were compared with those who received a placebo or no LSD. Successful post-treatment adjustment was more closely associated with pretreatment employment level, marital status, and completion of the treatment program than with LSD administration.

Methylenedioxyamphetamine (MDA)–Subjective Effects

Journal of Psychedelic Drugs January 1, 1974 Ibrahim Turek, Robert A. Soskin, A. A. Kurland 59 citations

Methylenedioxyamphetamine (MDA) produces a subjective experience distinct from both LSD and amphetamine, characterized by enhanced emotional communication, empathy, and a sense of closeness to others, without the perceptual distortions typical of LSD or the drive of amphetamine. The effects are described as warm, loving, and facilitative of interpersonal contact, with users reporting a clear sensorium and minimal anxiety. The article notes that MDA's effects are dose-dependent and that it can be used therapeutically to enhance psychotherapy by promoting emotional openness.

MDA-ASSISTED PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS

The Journal of Nervous and Mental Disease October 1, 1976 Richard Yensen, Francesco B. Di Leo, John Rhead et al. 51 citations

Ten neurotic outpatients (five men, five women) received up to 75 hours of psychotherapy over 2 to 6 months, with 3,4-methylenedioxyamphetamine (MDA) administered as an adjunct in two to four sessions. The drug was well tolerated with no serious side effects. Pre- and post-treatment psychometric assessments, including the MMPI, Wittenborn Psychiatric Rating Scales, and Brief Psychiatric Rating Scale, showed significant reductions in depression, anxiety, and obsessive-compulsive traits, along with improvements in well-being and self-actualization. No patient worsened. A 6-month follow-up using the same measures plus a Social History Questionnaire supported these improvements.

THE USE OF LSD IN TIME-LIMITED PSYCHOTHERAPY

The Journal of Nervous and Mental Disease December 1, 1973 Robert A. Soskin 15 citations

Patients receiving LSD as an adjunct to psychotherapy showed no greater improvement than those receiving a placebo. In a randomized trial, 28 inpatients were assigned to two psychotherapy groups, one receiving five LSD sessions and the other five placebo sessions over 13 weeks. Both groups improved modestly, with no differential effects on self-report or clinical ratings. At an 18-month follow-up of 20 patients, the placebo group scored higher on emotional stability, conscientiousness, and social precision. Gains in adjustment were maintained regardless of treatment type. The findings and clinical impressions indicate that LSD is of minimal value for marginally motivated and psychologically unsophisticated individuals.